It's the question people type into Google at 11pm but rarely ask their doctor. Does Ozempic affect your sex drive? Will Mounjaro help or hurt your performance? What's going on down there when everything else about your body is changing?
The short answer is that GLP-1 medications can affect sexual function — in both directions. Which direction depends on your starting point, your sex, your baseline metabolic health, and the amount of weight you lose. The research is still catching up to the lived experience, but what we have so far is more nuanced and more interesting than a simple yes-or-no.
For men: the evidence leans positive
Multiple studies have found that GLP-1 medications improve erectile function in men, particularly those with obesity or type 2 diabetes — populations where erectile dysfunction is already common.
A retrospective cohort study found that men on long-acting GLP-1 medications, including semaglutide, showed meaningful improvements in erectile function scores compared to baseline (Lisco et al., 2024). Another study reported higher IIEF-5 scores — a standard measure of erectile function — in patients taking GLP-1 medications compared to those on insulin (Defeudis et al., 2022).
Tirzepatide may have an edge here. A recent analysis found that tirzepatide was associated with a lower risk of erectile dysfunction compared to sitagliptin, injectable semaglutide, and dulaglutide in men with type 2 diabetes (Cowart et al., 2025).
Why the improvement? The mechanisms are straightforward. Obesity is one of the strongest risk factors for erectile dysfunction. Excess body fat — especially visceral fat — promotes chronic inflammation, impairs blood vessel function, and disrupts hormone production. Weight loss reverses these processes. Blood flow improves. Inflammation decreases. And testosterone often rises.
A meta-analysis found that GLP-1 medications significantly increased total testosterone levels in men, with a substantial mean difference of 1.39 ng/mL alongside improvements in erectile function scores (Salvio et al., 2025). For men with obesity-related hypogonadism — where excess fat suppresses testosterone production — weight loss through GLP-1 medications can restore testosterone to healthy ranges without needing testosterone replacement therapy.
For women: more mixed, less studied
The research on women's sexual health with GLP-1 medications is thinner, and the picture is more complicated.
Weight loss and improved metabolic health generally benefit sexual function in women — better body image, more energy, improved hormonal balance. For women with PCOS (polycystic ovary syndrome), GLP-1 medications can improve insulin resistance and hormonal profiles, which may positively affect fertility and sexual function.
However, individual reports of reduced libido, genital dryness, and difficulty reaching orgasm have emerged. A case report documented a woman on tirzepatide who experienced decreased sexual drive, genital dryness, and orgasm difficulty — with scores on a standardised sexual function questionnaire dropping during treatment and improving after stopping (Mohammed et al., 2025). A separate case described a woman who developed anorgasmia on liraglutide and semaglutide, which resolved after switching to tirzepatide (Visvabharathy et al., 2025).
These are case reports — individual stories, not population-level data. They can't tell us how common these experiences are. But they validate what some women are reporting in online communities and deserve acknowledgment rather than dismissal.
The reward pathway theory
There's a plausible neurological explanation for why some people experience reduced libido on GLP-1 medications, and it connects to the same mechanism behind "food noise" reduction and the alcohol craving changes.
GLP-1 receptors in the brain's reward system don't distinguish neatly between types of pleasure. When the medication dials down the dopamine-driven desire for food, it may, for some people, also dial down other reward-driven desires — including sexual desire. A clinical review has discussed potential serotonergic effects on sexual desire, which would parallel how certain antidepressants (SSRIs) affect libido (Gelfand et al., 2025).
This doesn't appear to be a universal effect. Survey data from the Kinsey Institute suggests roughly equal numbers of GLP-1 users report increased (18%) and decreased (16%) desire — with the majority reporting no significant change. The individual variation is wide.
The practical takeaway
A large-scale analysis of the FDA's adverse event database found reports of erectile dysfunction, decreased libido, and orgasmic dysfunction among GLP-1 users — but the disproportionality signals were weak, suggesting these events are not dramatically more common than in the general population (Langroudi et al., 2025).
If you're experiencing sexual function changes on a GLP-1 medication, consider these factors. Rapid weight loss itself — not the medication — can temporarily disrupt hormones. Fatigue, nutritional deficiencies, and reduced caloric intake all affect sexual energy. Psychological adjustment to a changing body takes time. And some changes may reflect the reward pathway modulation that also reduces food and alcohol cravings.
Most sexual function changes on GLP-1 medications are temporary and resolve as your body adjusts to its new weight and hormonal equilibrium. If changes persist or are distressing, talk to your prescribing doctor. Adjusting the dose, switching medications, or addressing contributing factors (sleep, stress, nutrition) can help.
For many men — especially those with obesity-related erectile dysfunction — GLP-1 medications are likely to improve sexual function, not impair it. The weight loss, improved cardiovascular health, and testosterone recovery represent genuine physiological improvements.
For women, the picture is less clear. Monitor how you feel, communicate with your doctor, and don't assume that any change in libido is something you need to simply accept.
Key Studies & References
We base this guide on the strongest available peer-reviewed research so you can see exactly where the information comes from. Here are the most relevant and impactful studies we referenced:
-
Salvio et al. (2025) — A meta-analysis that found GLP-1 receptor agonists significantly increase total testosterone levels and lead to meaningful improvements in erectile function scores for men with obesity or type 2 diabetes. Read the full meta-analysis
-
Cowart et al. (2025) — Large real-world study comparing tirzepatide to semaglutide and other GLP-1 drugs; tirzepatide was linked to a lower risk of erectile dysfunction in men with type 2 diabetes. Read the study on PubMed
-
Lisco et al. (2024) — Retrospective analysis showing improved erectile function in men with type 2 diabetes using long-acting GLP-1 medications. Read the study on PubMed
-
Mohammed et al. (2025) — Detailed case report describing reduced sexual desire, genital dryness, and orgasm difficulties in a woman taking tirzepatide, with symptoms improving after discontinuation. Read the full case report on PMC
-
Kounatidis et al. (2025) — Narrative review exploring both the positive vascular/metabolic effects and potential reward-pathway impacts of GLP-1 medications on sexual function. Read the review on PMC
-
Langroudi et al. (2025) — Analysis of real-world reports from the FDA's FAERS database regarding sexual dysfunction signals with GLP-1 receptor agonists, finding that disproportionality signals were weak overall. Read the analysis on PubMed
These studies highlight an important pattern: many people experience improvements in sexual function thanks to weight loss and better metabolic health, while a smaller group reports temporary reductions in libido or other changes. Results vary significantly between individuals.
Medical Disclaimer: GLP-1 medications are not approved for treating sexual health issues. If you notice changes in libido, erectile function, or arousal, speak with your doctor. Individual experiences differ.